Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

businesswire.com
CERS The article announces Cerus Corporation's participation in the 2026 AABB Annual Meeting, including a workshop and presentations on their INTERCEPT products. The focus is on sharing scientific data and engaging with the transfusion medicine community, with no specific financial performance or future outlook mentioned.

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting CONCORD, Calif.--( BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies.

“We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences,” said Vivek Jayaraman, Cerus’ president and chief executive officer. “The meeting provides an important opportunity to share scientific data and engage with the transfusion medicine community.”

The following is a select list of Cerus-related presentations and abstracts. All presentation times are listed in Eastern Time (ET).

Cerus-Sponsored Industry Workshop at AABB

Oral Presentations

Poster Presentations

On display Sunday, October 18, and Monday, October 19, 2026

The full program of Cerus-related abstracts can be found at the following link: https://intercept-usa.com/2026-abstract-book/

Cerus representatives will be in the exhibition area at booth #915.

*Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus, INTERCEPT, and the Cerus logo are trademarks of Cerus Corporation.